Recent updates on the management of ocular sebaceous gland carcinoma

---

Review Article

Author Details : Rajendra Prakash Maurya*, Sneha Gupta, Syeed Mehbub Ul Kadir, Murtuza Nuruddin, Aalok Kumar, Manish Prajapat, Virendra Pratap Singh, Gaurav Pande, Swati Gautam, Varshika Panday

Volume : 9, Issue : 2, Year : 2023

Article Page : 56-67

https://doi.org/10.18231/j.ijooo.2023.013

Suggest article by email

Get Permission

---

Abstract

Ocular sebaceous gland carcinoma (SGC) is a relatively rare, slow growing, but most aggressive and life-threatening tumor. It accounts for around 1% of all cutaneous malignancies. In Caucasians, SGCs are rare accounting for 1-5.5% of eyelid malignancies with a high incidence rate (28-60%) reported in the Asian population. In most SGCs no obvious etiology has been identified but few cases are associated with Muir-Torre syndrome. The dysregulation of several cell signaling pathways has been reported in tumorigenesis of SGC. Recently genome sequencing of periocular SGC revealed several gene mutations like TP53 and RB1 genes. Ocular SGC is known as the ‘great masquerader’ as it mimics several benign and inflammatory conditions like chalazion and chronic blepharitis/ blepharoconjunctivitis which may be responsible for delayed diagnosis and high mortality. Clinico-pathologically ocular SGC can be broadly categorized into nodular and pagetoid subtypes. The latter is more aggressive and associated with a high rate of lymph node metastasis and recurrence hence requiring aggressive multimodal treatment. More aggressive features associated with poor prognosis include involvement of both eyelids, infiltrative growth pattern, multicentric in origin with a pattern of spread to surrounding structures like pagetoid spread, vascular, lymphatic and orbital invasion. Although wide surgical excision with tumor-free margin is the gold standard treatment for the localized nodular type of ocular SGC, but the management of advanced-stage disease, invasive or aggressive lesions and recurrence is challenging and often needs a multidisciplinary approach that can reduce the mortality rate in patients with SGC. In this review article, we report recent research in molecular pathogenesis, clinicopathological features, the importance of TNM staging, sentinel lymph node biopsy, map biopsy and immunohistochemical evaluation of tumor markers like p,Ki-67, bcl-1, and p. We also emphasized the treatment of ocular SGC, i.e. surgical excision & reconstruction, topical therapy, neoadjuvant chemotherapy, targeted therapy, and radiation therapy.
 

Keywords: Ocular sebaceous Carcinoma, Masquerades, Therapeutic target, Biomarkers, Prognostic markers, Metastasis, Recurrence

How to cite : Maurya R P, Gupta S, Kadir S M U, Nuruddin M, Kumar A, Prajapat M, Singh V P, Pande G, Gautam S, Panday V, Recent updates on the management of ocular sebaceous gland carcinoma. IP Int J Ocul Oncol Oculoplasty 2023;9(2):56-67

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.